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Accepted 14 January; published on WWW 9 March 1998Inactivation of p53 tumor-suppressor leads to genetic
instability and, in particular, to accumulation of cells with
abnormal numbers of chromosomes. In order to better
define the role of p53 function in maintaining genome
integrity we investigated the involvement of p53 in the
control of proliferation of micronucleated cells resulting
from abnormal chromosome segregation. Using cell lines
expressing temperature-sensitive (ts) p53 or containing
p53 genetic suppressor element (p53-GSE) we showed
that inhibition of p53 function increases the frequency of
cells with micronuclei. Immunofluorescence study
revealed that in REF52 cell cultures with both
spontaneous and colcemid-induced micronuclei the
proportion of p53-positive cells is considerably higher
among micronucleated variants as compared with their
mononuclear counterparts. Analysis of 12(1)ConA cells
expressing the b -galactosidase reporter gene under the
control of a p53-responsive promoter showed activation of
p53-regulated transcription in the cells with micronuclei.
Importantly, the percentage of cells manifesting specific
p53 activity in colcemid-treated cultures increased with
an augmentation of the number of micronuclei in the cell.
Activation of p53 in micronucleated cells was
accompanied by a decrease in their ability to enter S-
phase as was determined by comparative analysis of 5-
bromodeoxyuridine (5-BrdU) incorporation by the cells
with micronuclei and their mononuclear counterparts.
Inhibition of p53 function in the cells with tetracycline-
regulated p53 gene expression, as well as in the cells
expressing ts-p53 or p53-GSE, abolished cell cycle arrest
in micronucleated cells. These results along with the data
showing no increase in the frequency of chromosome
breaks in REF52 cells after colcemid treatment suggest
the existence of p53-mediated cell cycle checkpoint(s)
preventing proliferation of micronucleated cells derived
as a result of abnormal chromosome segregation during
mitosis. 
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SUMMARYINTRODUCTION
p53 plays an important role in the restriction of proliferation
of abnormal cells. Experimental evidence suggests that it
orchestrates a number of cellular responses to cytotoxic
stresses (for review see Hartwell and Kastan, 1994; Chernova
et al., 1995; Ko and Prives, 1996; Levine, 1997). Functioning
as a transcription factor p53 up-regulates expression of genes
that contain p53-binding elements including waf1/cip1 and
gadd45 whose products contribute to cell cycle arrest (El Deiry
et al., 1993, 1994; Dulic et al., 1994; Zhan et al., 1994; Harper
et al., 1995), and bax, fas and a set of PIG genes whose
products may contribute to induction of apoptosis (Miyashita
et al., 1994a; Miyashita and Reed, 1995; Owen-Schaub et al.,
1995; Polyak et al., 1997). In addition, p53 can down-regulate
a number of genes, probably through direct interaction with
basal transcription factors such as TBP and CBP (Seto et al.,
1992; Ragimov et al., 1993; Horikoshi et al., 1995). Among
these genes is bcl2, a suppressor of apoptosis (Miyashita et al.,1994a,b). Thus, p53 activates cell cycle checkpoints and
triggers apoptosis preventing growth of damaged cells as well
as proliferation of undamaged cells under unfavorable
conditions (Hartwell and Kastan, 1994; Chernova et al., 1995;
Cox and Lane, 1995; Jacks and Weinberg, 1996; Ko and Prives,
1996; Levine, 1997). 
One of the consequences of the loss of p53 safeguard activity
is genetic instability. It is noteworthy, that p53 abnormalities
induce changes in chromosome number along with
chromosome breaks and DNA recombinations. In fact, an
increased rate of accumulation of aneuploid cells was found in
p53-deficient mouse fibroblasts and in human colorectal
carcinoma cells expressing mutant p53 (Tsukada et al., 1993;
Carder et al., 1993; Agapova et al., 1996). It was supposed that
loss of p53 function can lead both to an increase in probability
of chromosome non-disjunction and to abrogation of negative
control of proliferation of cells with chromosome segregation
errors (Agapova et al., 1996). In order to analyze possible
pathways that can underlie the latter mechanism we decided to
978 A. A. Sablina and othersstudy the role of p53 in control of proliferation of cells
containing micronuclei resulting from abnormal chromosome
segregation during mitosis. In the present paper we show that
formation of micronuclei triggers p53 activation followed by
cell cycle arrest. p53-mediated activation of the cell cycle
checkpoint(s) by micronuclei may represent one of the
mechanisms by which normal p53 function prevents
accumulation of aneuploid cells. 
MATERIALS AND METHODS
Cell cultures
Cell lines with different states of endogenous p53 as well as their
derivatives expressing various p53 cDNAs were used. They included:
(i) rat embryo fibroblasts (REF) at 2-6 passages in vitro and their
subline containing the p53-GSE/22 (genetic suppressor element #22)
short C-terminal fragment of rat p53 cDNA that inhibits p53 function
via a dominant-negative mechanism (Ossovskaya et al., 1996); (ii)
spontaneously immortalized REF52 rat fibroblasts retaining
expression of the wild-type (wt)-p53 (Ishizaka et al., 1995) and their
subline with transduced p53-GSE/22; (iii) murine immortalized
fibroblasts 10(1) which are devoid of endogenous p53 expression
(Harvey and Levine, 1991) and their subline expressing murine
temperature-sensitive (ts)-Val135-p53, which at 32°C has
conformation and activities of wt-p53 but at 37°C behaves like a
typical mutant p53 (Mikhalovitz et al., 1990; Martinez et al., 1991).
As a control in this case we used 10(1) cells harboring insert-free
retroviral vector pPS/neo (Kopnin et al., 1995); (iv) murine wt-p53-
positive 12(1) immortalized fibroblasts (Harvey and Levine, 1991)
expressing bacterial b -galactosidase under the control of p53-
responsive promoter, kindly provided by Dr M. V. Chernov, Cleveland
Clinic Foundation, Cleveland (Komarova et al., 1997); and (v) human
TR9/7 fibroblasts with tetracycline-regulated expression of exogenous
wt-p53, kindly provided by Dr G. R. Stark, Cleveland Clinic
Foundation, Cleveland (Agarwal et al., 1995). In these cells the level
of p53 expression gradually increases upon decrease of tetracycline
concentration in culture medium: at 1.0 m g/ml p53 expression is not
detected while the withdrawal of tetracycline induces p53 expression
to the levels comparable with those observed after DNA damaging
insults (Agarwal et al., 1995). 
All cells were cultured in DMEM medium supplemented with 10%
fetal calf serum (Gibco Booklet, Scotland) in a humidified atmosphere
supplied with 5% CO2. TR9/7 cells were permanently maintained in
the medium with 1.0 m g/ml of tetracycline. For the experiments the
majority of cell types were plated at an initial density of 10-20 · 103Fig. 1. Restoration of microtubule cytoskeleton in colcemid-induced mi
(A) Immunofluorescence of a control colcemid-untreated REF52 cell af
(B) microtubule disorganization in the colcemid-treated cell; (C) cell wi
for 24 hours. Bars, 20 m m.cells/cm2 into LabTek Slide Chambers (Nunc Inc., Naperville,
Illinois, USA). TR9/7 cells were seeded at an initial density of 40 · 103
cells/cm2. 
Induction of micronuclei by colcemid treatment
At 14-16 hours after plating colcemid (Sigma) at a final concentration
of 0.03 m g/ml was added to the culture medium for 36 hours. Then
cells were washed twice with Hanks’ solution for 10-15 minutes and
placed in fresh growth medium. Further experiments were performed
after additional culturing in colcemid-free medium for 24 hours
allowing restoration of microtubule cytoskeleton, as was determined
by staining with anti- a -tubulin DM1A monoclonal antibody (Sigma)
(Fig. 1). For visualization of micronuclei the cells were counterstained
with Hoechst #33258 (Sigma). 
Immunufluorescence analysis of p53 expression 
Cells were washed twice with phosphate buffered saline (PBS) at 35-
37°C, fixed with 4% formaldehyde for 15 minutes at room
temperature and incubated in a mixture of methanol/acetone (1:1) at
- 20°C for 10 minutes. Then methanol/acetone was replaced gradually
with PBS and cells were stained with PAb421 monoclonal antibodies
specific to p53. PAb421/p53 complexes were visualized by indirect
staining with Biotin-conjugated anti-mouse IgG and FITC-labeled
Streptavidin (both Dianova, Germany). 
Analysis of p53-responsive transcription in mouse
12(1)ConA cells by b -galactosidase staining
Cells were washed 5-6 times with PBS at 35-37°C, fixed with 1%
glutaraldehyde for 15 minutes at room temperature. For staining cells
were incubated overnight in a solution of 0.2% X-gal (Sigma), 3.3
mM K Fe4(CN)6, 3.3 mM K3Fe(CN)6 and 1 mM MgCl2 at 35-37°C.
Analysis of 5-bromodeoxyuridine (5-BrdU) incorporation
5-BrdU (Serva) at a final cocentration 10 - 5 M was added to the
culture medium for 5 hours. After incubation with 5-BrdU cells were
washed 2-3 times with PBS at 35-37°C, fixed with 4% formaldehyde
for 15 minutes at room temperature, permeabilized with 1% Triton
X-100 in buffer M (50 mM imidazole, 50 mM KCl, 0.5 mM MCl2,
0.1 mM EDTA, pH 6.8), containing 4% polyethylene glycol (Mr
40,000) for 3 minutes and hydrolysed with 4 M HCl at room
temperature for 10 minutes. 5-BrdU incorporation was visualized by
indirect immunostaining with BU-33 monoclonal mouse antibody
specific to 5-BrdU (Sigma) and TRITC-conjugated anti-mouse IgG
(Sigma). 
Analysis of chromosome breaks
Chromosomal slides were prepared by routine methods. In each case
50-100 metaphases were analyzed. cronucleated REF52 cell after drug withdrawal.
ter staining with DM1A monoclonal antibody specific to a -tubulin;
th colcemid-induced micronuclei after incubation in drug-free medium
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The frequency of cells with micronuclei is
dependent on the p53 state
To assess the possible role of p53 in restriction of
micronucleated cells we first compared the frequency of these
cells in cultures with functional or inactivated p53. For this
purpose two model systems were used: (i) spontaneously
immortalized murine fibroblasts which are either p53-positive
[12(1)ConA cell line], or p53-negative [10(1)neo cell line], or
express exogenous temperature-sensitive p53 [10(1)Val135
cell line]; and (ii) primary (REF) and immortalized (REF52)
rat embryo fibroblasts that express functional p53, or their
derivatives expressing dominant-negative p53 fragment
(REF/GSE22 and REF52/GSE22 cell lines). 
We have found that p53-deficient murine fibroblasts 10(1)
show a higher percentage of micronucleated cells as compared
with p53-positive 12(1)ConA cells (Table 1). The data obtained
with 10(1) cells expressing exogenous ts-p53 provide
additional evidence for participation of p53 in control of
proliferation of cells with micronuclei. Similar percentages of
micronucleated cells were found in 10(1)Val135 cultures
permanently incubated at the non-permissive temperature
(37°C) and in the control 10(1)neo cell line (Table 1). However,
after incubation at the permissive temperature (32°C) for 96
hours the percentage of micronucleated cells was significantly
decreased (Table 1). Evidently, the restoration of wt-p53
activity causes elimination of micronucleated variants from a
population of mouse 10(1) cells. In contrast, inactivation of p53
function in REF and REF52 cells by dominant negative p53
fragment resulted in substantial increase in the fraction of cells
with micronuclei (Table 2). Taken together these data strongly
suggest the existence of p53-dependent mechanisms that
prevent accumulation of abnormal micronucleated cells. Table 1. Frequency* of micronucleated cells in mouse cell
lines with various p53 states 
Temperature Cells with
Cell line of incubation p53 state micronuclei (%)*
10(1)neo 37°C - 24.5– 1.7
32°C† - 22.0– 1.6
10 (1)Val135 37°C Mutant 22.0 – 1.6
32°C† wt 14.0– 1.0
12(1)ConA 37°C wt 3.2– 0.2
*In each case 500-1,000 cells were analyzed.
†Cells permanently cultured at 37°C, were incubated at 32°C for 96 hours. 
Table 2. Influence of p53 inactivation by p53-GSE on
frequency of cells with micronuclei in rat embryo
fibroblasts (REF) and REF52 cell line
Cells p53-GSE Cells with micronuclei (%)*
REF - <0.1
+ 10.3– 0.3
REF52 - 6.5– 0.2
+ 12.9– 0.4
*In each case 1,000 cells were analyzed.Activation of p53 in cells with micronuclei 
Next we decided to test whether formation of micronuclei can
activate p53 function. Since it is known that micronuclei can
arise as a result of either abnormal chromosome segregation,
or chromosome breaks (Nusse et al., 1987; Hennig et al., 1988)
we analyzed both spontaneously derived, and colcemid-
induced micronucleated cells. It has been shown that colcemid
does not cause a clastogenic effect (Brown and Bick, 1986) and
induces formation of micronuclei through disruption of the
spindle. In fact, while 50-60% of spontaneously derived
micronuclei consist of acentric DNA fragments (probably
arising as the result of chromosome breaks), almost all
colcemid-induced micronuclei contain one or several
kinetochores (i.e. whole chromosomes) (Nusse et al., 1987;
Hennig et al., 1988; Stopper, 1994). Under the colcemid
treatment conditions that were used in this study (0.03 m g/ml
for 36 hours) the majority of REF52 cells became
micronucleated while the number of chromosome breaks was
not increased (Table 3). So, this approach allowed us to
minimize the contribution of chromosome breaks to activation
of p53 in micronucleated cells. 
DNA damage as well as many other insults leads to p53
stabilization and an increase in its intracellular content (for
review see Ko and Prives, 1996; Levine, 1997). To test whether
a similar mechanism of p53 activation can be observed in
micronucleated cells we performed an immunofluorescence
study of REF52 cell cultures with spontaneously derived or
colcemid-induced micronuclei. In both cases we have found
that a higher proportion of micronucleated cells stains withFig. 2. Comparison of p53 expression in micronucleated and
mononuclear cells. Staining with Hoechst #33258 DNA-binding dye
revealed in the field the cell containing micronucleus (arrow) as well
as mononuclear cell (A), while immunostaining with monoclonal
antibody specific to p53 displayed only the cell with micronucleus
(arrow) but not mononuclear counterpart (B). Bar, 20 m m.
980 A. A. Sablina and others
Table 3. Influence of colcemid treatment used for
induction of micronuclei on frequency of chromosome
breaks in REF52 cells 
Cells with micronuclei Metaphases with 
(%) chromosome breaks (%)
Control 6.5– 0.2 8.0– 1.5
Colcemid* 55.1– 3.1 10.0– 1.8
*Colcemid at a final concentration 0.03 m g/ml was added for 36 hours.anti-p53 antibodies as compared with normal mononuclear
cells (Figs 2, 3A). Without colcemid treatment the percentage
of p53-positive cells among micronucleated cells was quite low
(1.6±0.1%), yet nearly 20-fold higher than that among
mononuclear cells (0.1±0.05%). Specific p53 staining in such
a small proportion of micronucleated cells might be explained
either by low sensitivity of the used method that does not allow
detection of p53 in all the cells where it was induced, or by
accumulation of p53 only in a proportion of the micronucleated
cells. After colcemid treatment the number of p53-positive
cells significantly increased. This can be explained by residualFig. 3. Frequency of micronucleated and mononuclear cells stained
with anti-p53 antibody in REF52 cultures (A) or showed p53-
regulated b -galactosidase gene expression in 12(1)ConA cell cultures
(B). Both spontaneously derived and colcemid-induced
micronucleated cells were characterized by higher proportion of cells
showing p53 expression as compared with mononuclear
counterparts. (In each case 500-1,000 of mononuclear and 200-500
micronucleated cells were analyzed.) 
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(Tishler et al., 1995) that persists even after 24 hours of
incubation in colcemid-free medium. However, in colcemid-
treated cultures the clear difference between the ability of
micronucleated and mononuclear cells to stain for p53 was
retained (45.8±3.2% vs 6.7±0.3%), see Fig. 3A. Apparently,
micronucleated cells are characterized by a further increase in
p53 expression over an already elevated basal level that allows
visualization of p53 expression in a considerably larger
proportion of micronucleated cells. In any case the revealed
difference between the frequency of p53-positive mononuclear
and micronucleated cells in both colcemid-treated and
untreated cultures is in agreement with the suggestion that p53
is activated in cells with micronuclei. 
It was shown, however, that p53 accumulation does not
obviously lead to enhancement of its activity (Chernov and
Stark, 1997). Moreover, in some cell systems an increase in
p53 expression is accompanied by inactivation rather than by
activation of p53 function. For example, expression of some
viral oncoproteins which bind to p53 (SV40 T-antigen and
adenoviral E1B) as well as introduction into the cell of
dominant-negative p53-GSEs lead to stabilization of
transcriptionally inactive p53 (Tiemann et al., 1995; Lowe and
Ruley, 1993; Ossovskaya et al., 1996). Also, a high level of
functionally inactive wild-type p53 was observed in
teratocarcinoma cells (Lutziker and Levine, 1996). In order to
detect p53 activation in micronucleated cells we used
12(1)ConA mouse fibroblasts expressing a bacterial b -
galactosidase reporter gene under the control of a p53-
responsive promoter (Komarova et al., 1997). We have found
that micronucleated cells showed a higher proportion of b -
galactosidase staining (i.e. p53 activity) as compared with their
mononuclear counterparts in both colcemid-treated and
untreated cultures (Figs 3B, 4). It is noteworthy that in
colcemid-treated cultures the percentage of b -galactosidase-
positive cells increased in parallel with the number of
micronuclei. Indeed, p53-dependent b -galactosidase
expression was found in about 30% of mononuclear cells, in
50-60% of cells with one or two micronuclei, and in 85-90%
of cells containing more than four micronuclei (Table 4). This
observation along with the data showing no increase in theFig. 4. b -Galactosidase staining of micronucleated (arrows) and
mononuclear cells in colcemid-treated 12(1)ConA cultures. Two
cells with multiple micronuclei show positive staining (large arrows)
while the cell with a single large-sized micronucleus (small arrow) as
well as two mononuclear cells remained unstained. Bar, 20 m m. 
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Table 4. Dependence of b -galactosidase staining on the
number of micronuclei in colcemid-treated 12(1)ConA
cells 
Number of Proportion of b -galactosidase-
micronuclei positive cells (%)*
0 29.8– 1.7 (210)
1 55.8– 7.5 (103)
3 73.1– 9.8 (54)
4 80.1– 10.5 (45)
5 84.6– 13.7 (16)
>6 90.0 – 9.3 (39)
*The ratio of the of number b -galactosidase-positive cells to the number of
analyzed cells with given number of micronuclei. The number of analyzed
cells is indicated in parenthesis.frequency of chromosomal breaks in colcemid-treated cells
(Table 3) strongly points to the emergence in micronucleated
cells of some p53-activating signals which are distinct from
DNA damage or disruption of microtubules. There is a formal
possibility of a reverse consequence of events: p53 activation
somehow promotes formation of micronuclei. However, this
possibility seems to be unlikely since in mouse 10(1)Val135
cells the ‘switching-on’ of the wild-type p53 function caused
a decrease rather than an increase in the frequency of
micronucleated cells (Table 1). 
Limited ability of cells with micronuclei to enter S-
phase
One of the possible outcomes of p53 activation in
micronucleated cells might be the cell cycle arrest that prevents
accumulation of cells with abnormally segregated
chromosomes. To check this supposition we tested the ability
of micronucleated cells to enter S phase of the cell cycle. Three
model systems were used: (i) immortalized REF52 rat embryo
fibroblasts which express or do not express dominant-negative
p53-GSE/22; (ii) murine immortalized fibroblasts which are
either p53-negative [10(1)neo cell line], or express exogenous
ts-p53 [10(1)Val135 cell line]; and (iii) immortalized TR9/7
human fibroblasts with tetracycline-regulated expression of
exogenous p53. The ability of the cells to enter S phase was
assessed by analysis of 5-BrdU incorporation in
unsynchronized cultures after labeling for 5 hours. 
First we have found that in REF52 cells cultures expressing
endogenous wild-type p53 a considerably lower portion of
micronucleated cells was able to incorporate 5-BrdU as
compared with mononuclear cells. The expression of p53-Table 5. Influence of inhibition of p53 function by GSE22 on
to enter
Colcemid Cells with 
Cell line treatment micronuclei (%)*
REF52 - 6.5– 0.2
+ 41.7 – 2.0
REF52/GSE22 - 12.9– 0.4
+ 53.1 – 2.6
*Related to the number of all analyzed cells in given culture (1,000).
†Related to the number of all analyzed mononuclear cells in given culture (1,0
‡Related to the number of all analyzed cells with micronuclei in given culture GSE22 in REF52 cells that inhibits at least some of the p53
activity (Ossovskaya et al., 1996) eliminated the difference
between mononuclear and micronucleated cells in their ability
to enter S phase (Table 5). The dependence of the frequency
of 5-BrdU-positive micronucleated cells upon the p53 state
was further confirmed by analysis of murine 10(1) fibroblasts
expressing ts-p53. At the non-permissive temperature (37°C)
allowing expression of inactive p53 the number of 5-BrdU-
positive cells with micronuclei practically did not differ from
that observed in control p53-negative 10(1)neo subline.
However, shifting to the permissive temperature (32°C) that
results in restoration of p53 function caused a significant
decrease in the ability of micronucleated cells to enter S phase
(Table 6). Similar results were obtained in experiments with
TR9/7 cells allowing us to compare the ability of various levels
of p53 expression to arrest the cell cycle in mononuclear and
micronucleated cells. Under conditions permitting minimal
expression of p53 (1.0 m g/ml of tetracycline) mononuclear and
micronucleated cells show similar percentages of 5-BrdU
positiveness (Fig. 5). A stepwise decrease in tetracycline
dosages that leads to progressive increase in p53 expression
levels resulted in gradual diminishing of 5-BrdU-incorporation
that was most prominent in micronucleated cells indicative of
their decreased ability to enter the S-phase of the cell cycle.
Such effect was observed in the cells with both spontaneously
derived (Fig. 5A) and colcemid-induced micronuclei (Fig. 5B). 
It is noteworthy that in colcemid-treated TR9/7 cultures
repression of p53 function (1.0 m g/ml of tetracycline)
eliminated the difference between micronucleated and
mononuclear cells, but did not prevent the decrease in the
number of 5-BrdU-positive mononuclear cells (from
54.9±3.2% to 36.6±1.5%; see Fig. 5) which evidently resulted
from disruption of microtubules. Similarly, in REF52 cells
expression of dominant-negative p53-GSE22 abolished the
difference in the number of cycling mononuclear and
micronucleated cells, however, it did not influence partial cell
cycle arrest observed in mononuclear cells after colcemid
treatment (Table 5). It is possible that along with p53-
dependent mechanisms, p53-independent mechanisms are
responsible for the cell cycle arrest in colcemid-treated cells
and the latter might dominate after removal of the drug and
restoration of microtubule cytoskeleton. Also, the possibility
cannot be excluded that disruption of microtubules generates
much stronger signals for p53 induction than micronuclei
formation does, and the minimal basal quantities of p53 which
might be present in untreated TR9/7 and REF52/GSE22 cells
(as a result of leakage of the promoter governing p53 the ability of mononuclear and micronucleated REF52 cells
 S phase
5-BrdU-labeled 5-BrdU-labeled 
mononuclear cells (%)† micronucleated cells (%)†
42.0– 2.4 12.5– 0.8
23.0– 1.5 4.5– 0.3
57.2– 2.9 56.5– 4.6
21.2– 1.5 21.1– 0.9
00).
(300-500).
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Fig. 5. Influence of various levels of p53 expression on the
ability of monuclear and micronucleated TR9/7 cells to
incorporate 5-bromodeoxyuridine. In cultures with
significant levels of p53 expression (0.01-0.05 m g/ml of
tetracycline) both spontaneusly derived and colcemid-
induced micronucleated cells show decreased ability to
enter S-phase. Repression of p53 function (1.0 m g/ml of
tetracycline) eliminates the cell cycle arrest in cells with
micronuclei. (In each case 500-1,000 of mononuclear and
200-500 micronucleated cells were analyzed). expression and incomplete inhibition of the p53 function by
GSE22, respectively) are sufficient to be amplified to the
levels/activities promoting the cell cycle arrest in response to
colcemid treatment, but insufficient to induce p53-mediated
arrest in micronucleated cells.
Putative cell cycle checkpoint(s) activated in
micronucleated cells 
Taken together our results suggest that abnormal chromosome
segregation leading to formation of micronuclei can trigger p53
activation and cell cycle arrest. These data allow us to suppose
the existence of cell cycle checkpoint(s) that restrict(s)
proliferation of cells which either contain additional nuclear
structures or have alterations in DNA content (or chromosome
number). The former seems to be more likely. In fact, we have
observed a correlation between the number of micronuclei and
the extent of p53 activation. In the 12(1)ConA cell line the
proportion of cells showing p53-driven reporter gene
expression increased with an augmentation of the number of
micronuclei (see Table 4). In addition we found no difference
in p53 activity in the cells with single small-sized and large-
sized micronuclei (data not shown). Probably, quantitative
changes in DNA content or chromosome number did not affect
p53 response. 
Activation of p53 can cause cell cycle arrest in different
phases. In the majority of cases delay of the G1/S transition is
observed (for review see Ko and Prives, 1996; Levine, 1997),
however arrest in G2 (Agarwal et al., 1995; Stewart et al.,
1995) and in S (Mikhalovitz et al., 1990; Ishizaka et al., 1995)Table 6. Ability of micronucleated  cells to enter S-phase in
mouse cell lines with various p53 states
Temperature % of 5-BrdU-labeled cells 
Cell line of incubation p53 state with micronuclei*
10(1)neo 37°C - 14.0– 1.0
32°C - 12.0– 0.9
10 (1)Val 135 37°C Mutant 11.0– 0.9
37°C wt 2.0– 0.1
*Related to the number of all 5-BrdU-positive cells. In each case 300-500
cells were analyzed.was also described. The key role in p53-induced cell cycle
arrest is played by p21waf1, which binds to and inhibits a
number of cyclin and Cdk (cyclin-dependent kinase)
complexes: cyclin D1-Cdk4, cyclin E-Cdk2, cyclin A-Cdk2,
and cyclin B-Cdc2 (El-Deiry et al., 1994; Dulic et al., 1994;
Polyak et al., 1996; Levine, 1997). In addition p21waf1 binds
directly to PCNA and inhibits its function as a DNA
polymerase processivity factor in DNA replication (for review
see Kelman, 1997). The products of other p53-responsive
genes such as gadd45 can also contribute to cell cycle arrest
(Zhan et al., 1994). Variations in the points of the cycle in
which the cells arrest in response to p53 activation may reflect
differences in cell context, depending on the cell cycle phases
of target cells, tissue-specificity, relative activity of various
p53-downstream genes, etc. For example, activation of p53 in
early G1 inhibits the G1/S transition, while the cells which
passed the critical point in late G1 do not show G1 arrest in
response to p53 activation and can be blocked further in G2
(Linke et al., 1997). It seems quite probable that
micronucleated cells can be blocked in G1 following mitosis
in which abnormal chromosome segregation leading to
formation of micronuclei had occurred. However, the arrest in
other phases cannot formally be excluded. It should be noted
that cell cycle arrest evidently is not the sole mechanism by
which p53 activation can prevent accumulation of
micronucleated cells: in addition it can induce apoptosis. The
decision of whether p53 will induce cell cycle arrest or
apoptosis depends on many factors such as tissue specificity,
growth factor availability, activity of the p53-Rb-E2F
pathway, etc. (reviewed by Ko and Prives, 1996; Levine, 1997;
Oren and Prives, 1996). 
While the downstream pathways responsible for p53-
induced cell cycle arrest are established, the upstream
mechanisms of p53 activation in micronucleated cells remain
unclear. Two possibilities exist: (i) micronuclei themselves
trigger p53 activation; and (ii) p53 is induced not in response
to formation of micronuclei, but as a result of some other
cellular changes that regularly accompany appearance of
micronuclei. For instance, one intriguing possibility could be
that an increase in the number of centrosomes and/or
microtubule-organizing centers (MTOC) serves as a signal
activating p53 in micronucleated cells. This supposition is
983p53 Activation in cells with micronucleibased on the observation of Fukasawa et al. (1996) who
showed amplification of MTOC in p53-deficient cells and
hypothesized the role of p53 in the regulation of centrosome
replication. However, some data indicate that the number of
centrosomes is dependent on the ploidy level, but not on the
number of nuclei (Onishchenko, 1978; Radley and Scurfield,
1980). Further ideas and studies will be needed to understand
the mechanisms of p53 activation in micronucleated cells. 
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